Please login to the form below

Not currently logged in
Email:
Password:

Cytos Biotechnology

This page shows the latest Cytos Biotechnology news and features for those working in and with pharma, biotech and healthcare.

Alzheimer's disease pipeline takes multiple hits

Alzheimer's disease pipeline takes multiple hits

modulator EVP 0962 (EnVivo Pharmaceuticals); the metal protein-attenuating compound called PBT 2 (Prana Biotechnology); and ELND 005 (Speranza Therapeutics). ... Phase II agents include vanutide cridificar (Elan, Pfizer, Janssen Alzheimer Immunotherapy),

Latest news

  • Kicking the habit

    Vaccination route. It appears that vaccination could also be an option in modern day smoking cessation therapy, of which the most advanced are Nabi Biopharmaceuticals' NicVAX and Cytos Biotechnology's ... Cytos has completed a phase II study in 341

  • Silent, yet deadly

    CYT 006 AngQb, from Cytos Biotechnology, is another new therapeutic vaccine in development.

  • Deals in development

    been evaluated in patients with lung cancer, prostate cancer and ovarian cancer; and Cytos Biotechnology's NIC-002 ó a therapeutic vaccine for the potential treatment of nicotine dependency. ... The deal that brought NIC-002 to the Novartis portfolio

  • News in Brief, May 30, 2007

    Cytos reports results from a phase I/IIa psoriasis vaccine study. Switzerland-headquartered Cytos Biotechnology has reported results from a placebo-controlled, double-blind combined phase I/IIa study with ... Cangene manufactures VIG in its Winnipeg

  • News in brief, May 02, 2007

    Cytos Biotechnology enters nicotine vaccine agreement with Novartis. Swiss biotechnology company, Cytos, has entered into an exclusive global commercial license agreement with Novartis, to develop, manufacture and commercialise CYT002-NicQb, a

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Exclusive commercial licence. 165. Cytos Biotechnology. Checkmate Pharmaceuticals. CYT 003 and VLP [virus like particle] platform in oncology.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Corporate acquisition. 545. Cytos Biotechnology/ OnCore. Access to virus like particle (VLP) platform for the treatment and prevention of hepatitis B with an option to other viral diseases.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics